Table 1 p-AMPK expression in colorectal cancer, and clinical, pathologic and molecular features

From: Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer

Clinical, pathologic

 

p-AMPK expression

 

or molecular feature

Total N

Negative

Positive

P- value

All cases

718

309

409

 

Sex

0.051

 Male

259 (36%)

99 (32%)

160 (39%)

 

 Female

459 (64%)

210 (68%)

249 (61%)

 

Age (years)

 

 ⩽59

143 (20%)

71 (23%)

72 (18%)

0.071

 60–69

301 (42%)

116 (38%)

185 (45%)

 

 ⩾70

274 (38%)

122 (39%)

152 (37%)

 

BMI

   

0.69

 <30 kg m–2

594 (83%)

254 (82%)

340 (83%)

 

 ⩾30 kg m–2

123 (17%)

55 (18%)

68 (17%)

 

Family history of colorectal cancer

0.66

 (−)

554 (77%)

236 (76%)

318 (78%)

 

 (+)

164 (23%)

73 (24%)

91 (22%)

 

Tumour location

0.61

 Proximal colon (cecum to transverse)

347 (49%)

155 (51%)

192 (48%)

 

 Distal colon (splenic flexure to sigmoid)

220 (31%)

89 (29%)

131 (32%)

 

 Rectum

140 (20%)

61 (20%)

79 (20%)

 

Stage

0.16

 I

160 (22%)

55 (18%)

105 (26%)

 

 II

214 (30%)

100 (32%)

114 (28%)

 

 III

204 (28%)

91 (29%)

113 (28%)

 

 IV

101 (14%)

45 (15%)

56 (14%)

 

 Unknown

39 (5.4%)

18 (5.8%)

21 (5.1%)

 

Tumour grade

0.0009

 Low

655 (92%)

269 (88%)

386 (95%)

 

 High

60 (8.4%)

38 (12%)

22 (5.4%)

 

Tumour border

0.80

 Expansile

543 (86%)

237 (86%)

306 (85%)

 

 Infiltrative

90 (14%)

38 (14%)

52 (15%)

 

p-MAPK3/1 expression

 (−)

469 (70%)

227 (80%)

242 (63%)

<0.0001

 (+)

202 (30%)

57 (20%)

145 (37%)

 

TP53 expression

0.055

 (−)

423 (59%)

194 (63%)

229 (56%)

 

 (+)

290 (41%)

112 (37%)

178 (44%)

 

FASN expression

0.024

 (−)

597 (84%)

267 (88%)

330 (81%)

 

 (+)

114 (16%)

38 (12%)

76 (19%)

 

MSI

0.0021

 MSI-low/MSS

591 (84%)

242 (79%)

349 (88%)

 

 MSI-high

113 (16%)

64 (21%)

49 (12%)

 

CIMP

 CIMP-low/0

596 (85%)

237 (78%)

359 (89%)

<0.0001

 CIMP-high

109 (15%)

66 (22%)

43 (11%)

 

LINE-1 methylation

 ⩾70%

121 (17%)

53 (18%)

68 (17%)

0.16

 50–69%

497 (71%)

220 (74%)

277 (70%)

 

 <50%

79 (11%)

26 (8.7%)

53 (13%)

 

BRAF mutation

0.048

 (−)

602 (85%)

250 (82%)

352 (88%)

 

 (+)

104 (15%)

54(18%)

50 (12%)

 

KRAS mutation

0.26

 (−)

438 (62%)

195 (64%)

243 (60%)

 

 (+)

271 (38%)

109 (36%)

162 (40%)

 

PIK3CA mutation

   

0.79

 (−)

538 (84%)

236 (84%)

302 (83%)

 

 (+)

106 (16%)

45 (16%)

61 (17%)

 
  1. Abbreviations: BMI=body mass index; CIMP=CpG island methylator phenotype; FASN=fatty acid synthase; MSI=microsatellite instability; MSS=microsatellite stable; p-AMPK=phosphorylated AMP-activated protein kinase; p-MAPK3/1=phosphorylated mitogen-activated protein kinase.
  2. % Number indicated the proportion of cases with a given clinical, pathologic or molecular feature among all cases, p-AMPK-negative cases or p-AMPK-positive cases.
Back to article page